Obesity paradox in heart failure: recent data discussed in a new editorial paper. #obesity #BMI #heartfailure #HF #cardiotwitter European Society of Cardiology Journals European Society of Cardiology ow.ly/IzNf50NpZK3

Important paper from the #EHJ that hopefully close the discussion on the #obesityparadox in #patients with #HF. Congratulations to Jawad Haider Butt MD & Prof. John McMurray 👏👏 EHJ Editor-in-Chief 👉 Newer indices that do not incorporate #weight showed that greater academic.oup.com/eurheartj/adva…

Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: no evidence for an ‘obesity-survival paradox’ according to new data. ow.ly/pkTE50Nq0z2 #HF #Heartfailure #Obesity #BMI #cardiotwitter European Society of Cardiology Journals European Society of Cardiology

Fantastic paper now online in #EurHeartJournal led by Jawad Haider Butt MD

Dapagliflozin in Black and White Patients With #HF Across the #EF Spectrum DAPA-HF ➕DELIVER 🎯composite of worsening HF or CV☠️. 👥74.5% White and 10.8% Black 🎯1️⃣16.8 in Black vs 11.6 per 100 person-years in White 👉dapagliflozin ⤵️ the risk of the primary endpoint to the

New in #JACCHF: Dapagliflozin confers similar relative risk reduction of clin outcomes in Black and White patients with Heart Failure, but Black patients benefit more due to higher absolute risk. shorturl.at/deEJZ JACC Journals Jawad Haider Butt MD Rudolf de Boer University of Glasgow Heart Failure Research Group

🆕 study in #JACCHF found the absolute benefits of the SGLT2 inhibitor dapagliflozin is > in Black patients in part due to having a higher incidence & prevalence of #heartfailure, but the relative benefits are consistent in both Black & White patients. bit.ly/3UeMAks

Will definitely be THE meeting for the latest in HF! Looking forward to presenting data on the efficacy & safety of #dapa according to #PAD status in pts with HF across the spectrum of LVEF in a pooled analysis of #DAPA-HF & #DELIVER!

🌏Geographic Differences in Patients With Acute Myocardial Infarction in The #PARADISE-MI Trial 👉Rates of incident HF varied almost 6️⃣-fold among regions 👉effect of sacubitril/valsartan was not modified by region. 📥 onlinelibrary.wiley.com/doi/epdf/10.10…

Very proud to share this analysis of #PARADIGMHF on anthropometric measures and adverse outcomes in 👥with #HFrEF published in Eur Heart J European Society of Cardiology Journals 🔥No evidence for an #obesity-survival paradox in #HFrEF 🔥📈adiposity defined by newer indices clearly associated with ⬆️#HF🏥

Forhold mellem talje og højde er bedre indikator end BMI til at vurdere prognosen for hjertesvigtpatienter, viser ny undersøgelse, som læge og ph.d.-studerende Jawad Butt står bag #sundpol buff.ly/3V8Gtyv

Post hoc analysis found gout common in HF and associated w/ worse outcomes. Benefit of dapagliflozin consistent in patients with & without gout. Dapagliflozin reduced initiation of new treatments for hyperuricemia and gout. ja.ma/3Us3hZX University of Glasgow Heart Failure Research Group Jawad Haider Butt MD

Geographic differences in patients with acute myocardial infarction: insights from the #PARADISE-MI. doi.org/10.1002/ejhf.2… HFAPresident #EJHF EJHF Editor-in-Chief Antonio Cannata' European Society of Cardiology European Society of Cardiology Journals Henry Han  Marco Metra Gianluigi Savarese Daniela Tomasoni Djawid Hashemi @JavadHButt

BE READY! Simultaneous publications at EJHF and presentations at ESC Congress! Attend ESC Congress and read online at EJHF

⚠️ #HF, #COPD and efficacy of dapagliflozin in HFmrEF/HFpEF: Insights from DELIVER⚠️ Just presented at the #ESCCongress and simultaneous publication on #EJHF HFAPresident Antonio Cannata' European Society of Cardiology European Society of Cardiology Journals Henry Han Djawid Hashemi Marco Metra Gianluigi Savarese

Prof. Køber & Dr. Jawad Haider Butt MD at #ESCCongress in a joint session on treatment of #HF w/ mid-range and preserved #EF Prof. Køber guided us nicely through RCTs in the area & Dr Jawad Haider Butt MD revealed new results from the #DELIVER trial – adding to the list of #dapa benefits!

🏃Dapagliflozin and Physical and Social Activity in #HFrEF #DAPA-HF 💊DAPA vs placebo 📌↗️mean KCCQ physical and social activity limitation scores at 8 months 📌↗️each of the individual components that comprise the physical and social activity limitations 📌largest

Interesting to see how long-term mortality changes in non-ischaemic HFrEF with the methods used for evaluation of adiposity. Nevertheless, no matter how you look at it, there seems to be a clear association between greater adiposity and higher mortality. doi.org/10.1002/ejhf.3…